Global Pulmonary Drug Delivery Systems Market Insights, Forecast to 2025
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
With better performance, the development of DPIs is faster than the MDIs. In the future, DPIs will occupy larger market share and replace the MDIs gradually. In addition, the market share of nebulizers will be smaller.
As WHO said, the COPD will become the world's third-leading cause of death by 2030. With the air pollution more and more serious, patients with respiratory diseases will be more and more, which means larger and larger demand for pulmonary drug delivery systems.
The global Pulmonary Drug Delivery Systems market is valued at 2560 million US$ in 2018 and will reach 3570 million US$ by the end of 2025, growing at a CAGR of 4.2% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pulmonary Drug Delivery Systems market based on company, product type, end user and key regions.
This report studies the global market size of Pulmonary Drug Delivery Systems in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pulmonary Drug Delivery Systems in these regions.
This research report categorizes the global Pulmonary Drug Delivery Systems market by top players/brands, region, type and end user. This report also studies the global Pulmonary Drug Delivery Systems market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Market size by Product
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
Market size by End User
COPD
Asthma
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Pulmonary Drug Delivery Systems market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pulmonary Drug Delivery Systems market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pulmonary Drug Delivery Systems companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pulmonary Drug Delivery Systems submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Pulmonary Drug Delivery Systems are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (M Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pulmonary Drug Delivery Systems market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
With better performance, the development of DPIs is faster than the MDIs. In the future, DPIs will occupy larger market share and replace the MDIs gradually. In addition, the market share of nebulizers will be smaller.
As WHO said, the COPD will become the world's third-leading cause of death by 2030. With the air pollution more and more serious, patients with respiratory diseases will be more and more, which means larger and larger demand for pulmonary drug delivery systems.
The global Pulmonary Drug Delivery Systems market is valued at 2560 million US$ in 2018 and will reach 3570 million US$ by the end of 2025, growing at a CAGR of 4.2% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pulmonary Drug Delivery Systems market based on company, product type, end user and key regions.
This report studies the global market size of Pulmonary Drug Delivery Systems in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pulmonary Drug Delivery Systems in these regions.
This research report categorizes the global Pulmonary Drug Delivery Systems market by top players/brands, region, type and end user. This report also studies the global Pulmonary Drug Delivery Systems market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Market size by Product
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
Market size by End User
COPD
Asthma
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Pulmonary Drug Delivery Systems market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pulmonary Drug Delivery Systems market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pulmonary Drug Delivery Systems companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pulmonary Drug Delivery Systems submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Pulmonary Drug Delivery Systems are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (M Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pulmonary Drug Delivery Systems market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
